Bartel DP. [2004]. MicroRNAs: genomics, biogenesis, mechanism, and function.cell, 116[2], 281–97.

Tang X, Tang G, Özcan S. Role of microRNAs in diabetes. Biochim Et Biophys Acta [BBA]-Gene Regul Mech. 2008;1779(11):697–701.

Article  CAS  Google Scholar 

Rangrez AY, Massy ZA, Metzinger-Le Meuth V, Metzinger L. [2011]. miR-143 and miR-145: molecular keys to switch the phenotype of vascular smooth muscle cells. Circulation: Cardiovasc Genet, 4[2], 197–205.

Ebrahimi R, Bahiraee A, Niazpour F, Emamgholipour S, Meshkani R. The role of microRNAs in the regulation of insulin signaling pathway concerning metabolic and mitogenic cascades: a review. J Cell Biochem. 2019;120(12):19290–309.

Article  CAS  PubMed  Google Scholar 

Mendonca A, Thandapani P, Nagarajan P, Venkatesh S, Sundaresan S. Role of microRNAs in regulation of insulin secretion and insulin signaling involved in type 2 diabetes mellitus. J Biosci. 2022;47(4):58.

Article  CAS  Google Scholar 

Jahantigh D, Mirani Sargazi F, Sargazi S, Saravani R, Ghazaey Zidanloo S, Heidari Nia M, Piri M. Relationship between functional miR-143/145 cluster variants and susceptibility to type 2 diabetes mellitus: a preliminary case-control study and bioinformatics analyses. Endocr Res. 2021;46(3):129–39.

Article  CAS  PubMed  Google Scholar 

Shahrokhi SZ, Saeidi L, Sadatamini M, Jafarzadeh M, Rahimipour A, Kazerouni F. [2022]. Can miR-145-5p be used as a marker in diabetic patients?. Arch Physiol Biochem, 128[5], 1175–80.

Hamburg M, N., Leeper J. N. [2015]. Therapeutic potential of modulating microRNA in peripheral artery disease. Curr Vasc Pharmacol, 13[3], 316–23.

Nigi L, Grieco GE, Ventriglia G, Brusco N, Mancarella F, Formichi C, …, Sebastiani G. [2018]. MicroRNAs as regulators of insulin signaling: research updates and potential therapeutic perspectives in type 2 diabetes. Int J Mol Sci, 19[12], 3705.

Kloosterman WP, Lagendijk AK, Ketting RF, Moulton JD, Plasterk RHA. [2007]. Targeted inhibition of miRNA maturation with morpholinos reveals a role for miR-375 in pancreatic islet development. PLoS Biol, 5[8], e203.

Holman GD, Kozka IJ, Clark AE, Flower CJ, Saltis J, Habberfield AD, …, Cushman SW. [1990]. Cell surface labeling of glucose transporter isoform GLUT4 by bis-mannose photolabel. Correlation with stimulation of glucose transport in rat adipose cells by insulin and phorbol ester. J Biol Chem, 265[30], 18172–9.

Pessin JE, Saltiel AR. [2000]. Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest 106[2], 165–9.

Shahrokhi SZ, Saeidi L, Sadatamini M, Jafarzadeh M, Rahimipour A, Kazerouni F. [2022]. Can miR-145-5p be used as a marker in diabetic patients?. Archives of Physiology and Biochemistry 128[5], 1175–80.

Furtado LM, Somwar R, Sweeney G, Niu W, Klip A. [2002]. Activation of the glucose transporter GLUT4 by insulin. Biochem Cell Biol, 80[5], 569–78.

Watson RT, Kanzaki M, Pessin JE. [2004]. Regulated membrane trafficking of the insulin-responsive glucose transporter 4 in adipocytes. Endocr Rev, 25[2], 177–204.

Wang J, Gao Y, Duan L, Wei S, Liu J, Tian L, …, Yang J. [2017]. Metformin ameliorates skeletal muscle insulin resistance by inhibiting miR-21 expression in a high-fat dietary rat model. Oncotarget, 8[58], 98029.

Chakraborty C, Doss CGP, Bandyopadhyay S, Agoramoorthy G. [2014]. Influence of miRNA in insulin signaling pathway and insulin resistance: micro-molecules with a major role in type‐2 diabetes. Wiley Interdisciplinary Reviews: RNA, 5[5], 697–712.

Huang Y, Yan Y, Xv W, Qian G, Li C, Zou H, Li Y. [2018]. A new insight into the roles of MiRNAs in metabolic syndrome. BioMed research international; 2018.

Jordan SD, Krüger M, Willmes DM, Redemann N, Wunderlich FT, Brönneke HS, …, Brüning JC. [2011]. Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated AKT activation and impairs glucose metabolism. Nat cell Biology 13[4], 434–46.

Wen F, Yang Y, Jin D, Sun J, Yu X, Yang Z. [2014]. MiRNA-145 is involved in the development of resistin-induced insulin resistance in HepG2 cells. Biochem Biophys Res Commun 445[2], 517–23.

Lee H, Jee Y, Hong K, Hwang GS, Chun KH. [2013]. MicroRNA-494, upregulated by tumor necrosis factor-α, desensitizes insulin effect in C2C12 muscle cells. PLoS ONE, 8[12], e83471.

Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, Macdonald PE, …, Stoffel M. [2004]. A pancreatic islet-specific microRNA regulates insulin secretion. Nature, 432[7014], 226–30.

Hardie DG. [2008]. AMPK: a key regulator of energy balance in the single cell and the whole organism. International journal of obesity, 32[4], S7-S12.

Joshi T, Singh AK, Haratipour P, Sah AN, Pandey AK, Naseri R, …, Farzaei MH. [2019]. Targeting AMPK signaling pathway by natural products for treatment of diabetes mellitus and its complications. J Cell Physiol, 234[10], 17212–31.

Li Y, Huang D, Zheng L, Cao H, Fan Z. [2019]. Effect of microRNA-141 on the development of diabetic nephropathy through regulating AKT/AMPK signaling pathway by targeting insulin receptor substrate 2. J Cell Biochem 120[5], 8008–15.

Entezari M, Hashemi D, Taheriazam A, Zabolian A, Mohammadi S, Fakhri F, …, Samarghandian S. [2022]. AMPK signaling in diabetes mellitus, insulin resistance and diabetic complications: a pre-clinical and clinical investigation. Biomedicine & Pharmacotherapy, 146, 112563.

Chen Y, Lin D, Shi C, Guo L, Liu L, Chen L, …, Xue Y. [2021]. MiR-3138 deteriorates the insulin resistance of HUVECs via KSR2/AMPK/GLUT4 signaling pathway. Cell Cycle 20[4], 353–68.

Holm LJ, Mønsted MØ, Haupt-Jorgensen M, Buschard K. [2020]. PPARs and the development of type 1 diabetes. PPAR research; 2020.

Holm LJ, Krogvold L, Hasselby JP, Kaur S, Claessens LA, Russell MA, …, Buschard K. [2018]. Abnormal islet sphingolipid metabolism in type 1 diabetes. Diabetologia, 61, 1650–61.

Janani C, Kumari BR. [2015]. PPAR gamma gene–a review. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 9[1], 46–50.

Van Rooij E, Kauppinen S. [2014]. Development of micro RNA therapeutics is coming of age. EMBO Mol Med 6[7], 851–64.

Chen T, Zhang Y, Liu Y, Zhu D, Yu J, Li G, …, Hong Z. [2019]. MiR-27a promotes insulin resistance and mediates glucose metabolism by targeting PPAR-γ-mediated PI3K/AKT signaling. Aging [Albany NY], 11[18], 7510.

Li X, Chen Y, Wu S, He J, Lou L, Ye W, Wang J. [2015]. microRNA-34a and microRNA-34c promote the activation of human hepatic stellate cells by targeting peroxisome proliferator-activated receptor γ. Mol Med Rep, 11[2], 1017–24.

Povero D, Panera N, Eguchi A, Johnson CD, Papouchado BG, de Araujo Horcel L, …, Feldstein AE. [2015]. Lipid-induced hepatocyte-derived extracellular vesicles regulate hepatic stellate cells via microRNA targeting peroxisome proliferator-activated receptor-γ. Cell Mol Gastroenterol Hepatol 1[6], 646–63.

Lu L, Wang J, Lu H, Zhang G, Liu Y, Wang J, …, Li Y, [2015]. MicroRNA-130a and-130b enhance activation of hepatic stellate cells by suppressing PPARγ expression: a rat fibrosis model study. Biochem Biophys Res Commun 465[3], 387–93.

Friedman RC, Farh KK-H. Christopher B. Burge, and David P. Bartel. Most mammalian mRNAs are conserved targets of microRNAs.“ Genome research 19, no. 1 [2009]: 92–105.

Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, Muth AN, …, Srivastava D. [2009]. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature, 460[7256], 705–10.

Xie H, Lim B, Lodish HF. [2009]. MicroRNAs induced during adipogenesis that accelerate fat cell development are downregulated in obesity. Diabetes, 58[5], 1050–7.

Takanabe R, Ono K, Abe Y, Takaya T, Horie T, Wada H, …, Hasegawa K. [2008]. Up-regulated expression of microRNA-143 in association with obesity in adipose tissue of mice fed high-fat diet. Biochem Biophys Res Commun 376[4], 728–32.

Xihua LIN, Shengjie T, Weiwei GUI, Matro E, Tingting TAO, Lin LI, …, Hong L. [2019]. Circulating mir-143-3p inhibition protects against insulin resistance in metabolic syndrome via targeting of the insulin-like growth factor 2 receptor. Translational Res, 205, 33–43.

Esau C, Kang X, Peralta E, Hanson E, Marcusson EG, Ravichandran LV, …, Griffey R. [2004]. MicroRNA-143 regulates adipocyte differentiation. J Biol Chem, 279[50], 52361–5.

Kajimoto K, Naraba H, Iwai N. [2006]. MicroRNA and 3T3-L1 pre-adipocyte differentiation. RNA, 12[9], 1626–32.

Lan S, Albinsson S. [2020]. Regulation of IRS-1, insulin signaling and glucose uptake by miR-143/145 in vascular smooth muscle cells. Biochem Biophys Res Commun, 529[1], 119–25.

Feng J, Xing W, Xie L. [2016]. Regulatory roles of microRNAs in diabetes. Int J Mol Sci 17[10], 1729.

Huang X, Liu G, Guo J, Su Z. [2018]. The PI3K/AKT pathway in obesity and type 2 diabetes. Int J Biol Sci 14[11], 1483.

Xu M, Mo YY. [2012]. The AKT-associated microRNAs. Cell Mol Life Sci, 69, 3601–12.

Kaur P, Reis MD, Couchman GR, Forjuoh SN, Greene JF Jr, Asea A. [2010]. SERPINE 1 links obesity and diabetes: a pilot study. J Proteom Bioinf, 3[6], 191.

Xin M, Small EM, Sutherland LB, Qi X, McAnally J, Plato CF, …, Olson EN. [2009]. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes & development, 23[18], 2166–78.

Elia L, Quintavalle M, Zhang J, Contu R, Cossu L, Latronico MV, …, Condorelli G. [2009]. The knockout of miR-143 and-145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death & Differentiation, 16[12], 1590–8.

Boettger T, Beetz N, Kostin S, Schneider J, Krüger M, Hein L, Braun T. [2009]. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the MiR-143/145 gene cluster. J Clin Invest 119[9], 2634–47.

Long X, Miano JM. [2011]. Transforming growth factor-β1 [TGF-β1] utilizes distinct pathways for the transcriptional activation of microRNA 143/145 in human coronary artery smooth muscle cells. J Biol Chem, 286[34], 30119–29.

Hergenreider E, Heydt S, Tréguer K, Boettger T, Horrevoets AJ, Zeiher AM, …, Dimmeler S. [2012]. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat cell Biology 14[3], 249–56.

Rondinone CM, Wang LM, Lonnroth P, Wesslau C, Pierce JH, Smith U. [1997]. Insulin receptor substrate [IRS] 1 is reduced and IRS-2 is the main docking protein for phosphatidylinositol 3-kinase in adipocytes from subjects with non-insulin-dependent diabetes mellitus. Proceedings of the National Academy of Sciences, 94[8], 4171–4175.

Xi G, Shen X, Wai C, White MF, Clemmons DR. [2019]. Hyperglycemia induces vascular smooth muscle cell dedifferentiation by suppressing insulin receptor substrate-1–mediated p53/KLF4 complex stabilization. J Biol Chem, 294[7], 2407–21.

Zhu Z, Xu T, Wang L, Wang X, Zhong S, Xu C, Shen Z. [2014]. MicroRNA-145 directly targets the insulin-like growth factor receptor I in human bladder cancer cells. FEBS Lett 588[17], 3180–5.

Zhao W, Zhao SP, Zhao YH. [2015]. MicroRNA-143/-145 in cardiovascular diseases. BioMed research international; 2015.

D’Alessandra Y, Carena MC, Spazzafumo L, Martinelli F, Bassetti B, Devanna P, …, Pompilio G. [2013]. Diagnostic potential of plasmatic MicroRNA signatures in stable and unstable angina. PLoS ONE, 8[11], e80345.

Meder B, Keller A, Vogel B, Haas J, Sedaghat-Hamedani F, Kayvanpour E, …, Rottbauer W. [2011]. MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction. Basic Res Cardiol, 106, 13–23.

Ono K. [2011]. MicroRNA links obesity and impaired glucose metabolism. Cell Res, 21[6], 864–6.

Li B, Fan J, Chen N. [2018]. A novel regulator of type II diabetes: MicroRNA-143. Trends in Endocrinology & Metabolism, 29[6], 380–8.

Avgeris M, Mavridis K, Tokas T, Stravodimos K, Fragoulis EG, Scorilas A. [2015]. Uncovering the clinical utility of miR-143, miR-145 and miR-224 for predicting the survival of bladder cancer patients following treatment. Carcinogenesis, 36[5], 528–37.

Su J, Liang H, Yao W, Wang N, Zhang S, Yan X, …, Wang Y, [2014]. MiR-143 and MiR-145 regulate IGF1R to suppress cell proliferation in colorectal cancer. PLoS ONE, 9[12], e114420.

Huang S, Guo W, Tang Y, Ren D, Zou X, Peng X. [2012]. miR-143 and miR-145 inhibit stem cell characteristics of PC-3 prostate cancer cells. Oncol Rep, 28[5], 1831–7.

Yan X, Chen X, Liang H, Deng T, Chen W, Zhang S, …, Ba Y. [2014]. miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer. Mol Cancer, 13, 1–14.

Riches K, Alshanwani AR, Warburton P, O’Regan DJ, Ball SG, Wood IC, …, Porter KE. [2014]. Elevated expression levels of miR-143/5 in saphenous vein smooth muscle cells from patients with type 2 diabetes drive persistent changes in phenotype and function. J Mol Cell Cardiol, 74, 240–50.

Aladel A, Khatoon F, Khan MI, Alsheweir A, Almutairi MG, Almutairi SO, …, Beg MMA. [2022]. Evaluation of miRNA-143 and miRNA-145 expression and their association with Vitamin-D status among obese and non-obese Type-2 Diabetic patients. J Multidisciplinary Healthc, 2979–90.

Li B, Fan J, Chen N. A Novel Regulator of type II diabetes: MicroRNA-143. Trends in Endocrinology & Metabolism. 2018;296:380–8.

Article  Google Scholar 

Barutta F, Bellini S, Guarrera S, Matullo G, Schalkwijk C, Stehouwer CD, …, Gruden G. [2022]. Association of serum MicroRNA-145-5p levels with microvascular complications of type 1 diabetes: the EURODIAB prospective complications study. Diabetes Res Clin Pract, 190, 109987.

Hao Y, Yang L, Liu Y, Ye Y, Wang J, Yu C, …, Li Y. [2021]. Mmu-miR-145a-5p accelerates diabetic wound healing by promoting macrophage polarization toward the M2 phenotype. Front Med, 8, 2589.

Chen H, Lan HY, Roukos DH, Cho WC. [2014]. Application of microRNAs in diabetes mellitus. J Endocrinol, 2221, R1-R10.

Lynn FC. [2009]. Meta-regulation: microRNA regulation of glucose and lipid metabolism. Trends in Endocrinology & Metabolism, 20[9], 452–9.

Moura J, Børsheim E, Carvalho E. [2014]. The role of micrornas in diabetic complications—special emphasis on wound healing. Genes, 5[4], 926–56.

Liu C, Feng H, Zhang L, Guo Y, Ma J, Yang L. [2023]. MicroRNA–143–3p levels are reduced in the peripheral blood of patients with gestational diabetes mellitus and influences pancreatic β–cell function and viability. Experimental and Therapeutic Medicine, 25[2], 1–11.